Newspaper disclosure for the FY ended 31.03.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Ltd has filed copies of the newspaper advertisement of its audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, published in Business Standard (English) and Aj Di Awaaz (Punjabi) on 31 May 2025. On a standalone basis, full-year revenue from operations fell sharply to Rs. 9,235.41 lakhs in FY25 from Rs. 13,220.40 lakhs in FY24, a drop of about 30%. The company reported a net loss of Rs. 1,034.28 lakhs for FY25, wider than the Rs. 864.81 lakhs loss in FY24, with a basic EPS of negative Rs. 7.86. In Q4 FY25, the standalone net loss narrowed to Rs. 193.87 lakhs compared with a Rs. 360.36 lakhs loss in Q4 FY24. On a consolidated basis, FY25 showed total income from operations of negative Rs. 9,485.84 lakhs and a net loss of Rs. 1,241.33 lakhs, with an EPS of negative Rs. 9.42.
This is essentially a regulatory newspaper publication of already-filed results and does not change the fundamental picture. The numbers are negative for shareholders, with revenue contraction and widened losses, though the sequential improvement in the Q4 standalone loss offers a small positive signal.